Vera Therapeutics shares updates on investigational therapy atacicept

Vera Therapeutics Inc. announced new data for its product candidate atacicept in two presentations at the European Renal Association Congress in France.
Presentations included results from the phase 2a JANUS trial in patients with IgA nephropathy (IgAN) and a post-hoc analysis of the phase 2 APRIL-SLE study in patients with systemic lupus erythematosus (SLE).
“We are excited to share these new data from the phase 2a JANUS clinical trial which we believe make atacicept the first known investigational therapeutic to reduce IgG autoantibodies, as well as its autoantigen, Gd-IgA1. Increased

Vera Therapeutics Inc. announced new data for its product candidate atacicept in two presentations at the European Renal Association Congress in France.
Presentations included results from the phase 2a JANUS trial in patients with IgA nephropathy (IgAN) and a post-hoc analysis of the phase 2 APRIL-SLE study in patients with systemic lupus erythematosus (SLE).
“We are excited to share these new data from the phase 2a JANUS clinical trial which we believe make atacicept the first known investigational therapeutic to reduce IgG autoantibodies, as well as its autoantigen, Gd-IgA1. Increased